Drugs, Health Technologies, Health Systems
Indication: For the treatment of adults with polycythemia vera
Sponsor: FORUS Therapeutics, Inc.
Recommendation: Reimburse with conditions
Summary
What Is the Reimbursement Recommendation for Besremi?
Canada’s Drug Agency (CDA-AMC) recommends that Besremi be reimbursed by public drug plans for the treatment of adult patients with polycythemia vera (PV) requiring cytoreductive therapy if certain conditions are met.
Why Did CDA-AMC Recommend Reimbursement?
The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that it is uncertain whether Besremi demonstrates acceptable clinical value versus hydroxyurea, peginterferon alfa-2a, and ruxolitinib in patients with PV requiring cytoreductive therapy. Given that Besremi is expected to be an alternative treatment to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea.
Evidence from a clinical trial failed to show that Besremi is noninferior to hydroxyurea at 12 months in patients with PV requiring cytoreductive therapy. However, the evidence from the completed long-term extension study suggested numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden when Besremi was compared to best available therapy. Evidence from an indirect treatment comparison showed that the complete hematological response was similar between Besremi and peginterferon alfa-2a in patients with PV.
pERC has established that there is significant unmet clinical need for additional cytoreductive treatment options for PV. Currently, there are limited treatment options with hydroxyurea used off-label as the main first-line option. There are challenges with hydroxyurea as patients may develop intolerance or resistance; hydroxyurea may be unsuitable for those of reproductive age; and there have been recent supply shortages, rendering the need for more treatment options for patients. pERC concluded that Besremi addresses a significant unmet need to a degree that justifies a positive recommendation despite the uncertainty in clinical value.
Which Patients Are Eligible for Coverage?
Besremi should only be reimbursed for the treatment of adult patients with PV requiring cytoreductive therapy if they are aged 18 years or older, with a confirmed diagnosis of PV and have good performance status.
For adult patients who require cytoreductive treatment but have not received any prior treatment, they must meet 1 of the following conditions: aged older than 60 years, previously documented cardiovascular or thromboembolic event(s), poor tolerance to phlebotomy, progressive splenomegaly, elevated platelet counts or thrombocytosis, or leukocytosis.
For adult patients who require cytoreductive treatment and are currently treated or have been pretreated with hydroxyurea, they must meet 1 of the following conditions: documented resistance to hydroxyurea or intolerance to hydroxyurea.
What Are the Conditions for Reimbursement?
Besremi should not be reimbursed if the patient experiences disease progression or unacceptable toxicity. Besremi should be prescribed by a clinician experienced in the diagnosis and management of PV. The cost of Besremi should be negotiated so that it does not exceed the cost of treatment with the least costly cytoreductive treatment reimbursed for PV. Important budget impact considerations and organizational implications must be addressed for health systems to be able to adopt Besremi.
Disease background: PV is a myeloproliferative neoplasm that is characterized by elevated red blood cell mass, which results in an elevated risk of vascular complications.
Patients with PV have an approximately 3-fold higher risk of arterial thrombosis and a 13-fold higher risk of venous thrombosis compared with the general population. Hemorrhagic complications occur in approximately 15% to 35% of patients. PV is also associated with a long-term risk of progression to myelofibrosis, or acute myeloid leukemia.
PV is a rare disease, as the incidence of PV in Canada is estimated at around 2 per 100,000 per year.
Indication and reimbursement request: Ropeginterferon alfa-2b (Besremi) has been approved by Health Canada for the treatment of adults with PV. The sponsor is seeking reimbursement for the treatment of adults with PV requiring cytoreductive therapy.
Drug under review: Ropeginterferon alfa-2b belongs to the class of type I interferons. It is available as a 500 mcg/mL prefilled syringe administered by subcutaneous injection. During titration, the starting dosage recommended in the product monograph is 100 mcg (or 50 mcg in patients who received prior cytoreductive therapy), which is gradually increased by 50 mcg every 2 weeks to the target dose of 500 mcg until optimal response is achieved or intolerance. Once optimal dose is achieved, it should be maintained in a 2-week administration interval for at least 1 year. After that, the dose may be adapted and/or the administration interval prolonged up to every 4 weeks, as appropriate for the patient.
Treatment costs: At the submitted price of $4,495.00 per single-dose prefilled syringe, the 28-day cost of ropeginterferon alfa-2b is expected to be $8,990.00 per patient in the first year and may reduce to $4,495.00 per patient in subsequent years, based on the Health Canada–recommended dosage and that only the 500 mcg strength prefilled syringe is currently available.
The patient groups (Heal Canada, the Leukemia & Lymphoma Society of Canada, and the Canadian MPN Network) noted the following regarding impacts of the disease, unmet needs, and important outcomes:
Due to their symptoms affecting daily activities, patients with PV often report changes in employment, reduction in social activities and travelling, and requiring assistance with daily tasks. Patients with PV experience negative impacts on their quality of life, such as psychological distress and treatment burden related to frequent clinic visits and phlebotomies.
Equity challenges related to the treatment of PV include travel burden among patients who live far away from specialists and treatment centres, financial barriers (e.g., lack of coverage, out-of-pocket costs), productivity impacts among younger patients (e.g., aged 50 years or younger), and worse PV-related complication burden among racialized populations.
Current treatments for PV are associated with undesirable side effects and do not adequately address the underlying disease process of PV, ongoing symptom burden, and procedural-related burden related to phlebotomy.
Goals of treatment for PV focused on meaningful improvements in daily life, which include maintenance of energy and function, reduced treatment-related burden (e.g., phlebotomies), long-term disease control, symptom control, and reduced fatigue.
The clinician groups (Canadian MPN Group and Ontario Health [Cancer Care Ontario] Hematology Cancer Drug Advisory Committee) and the clinical experts consulted by CDA-AMC noted the following regarding unmet needs arising from the disease and place in therapy for the drug under review:
There remains a need for treatments for PV that address underlying disease mechanisms, improve symptom control, and reduce clonal burden and the risk of disease transformation. Key limitations of treatment with phlebotomy include poor tolerance, geographic barriers in rural areas, treatment complications (e.g., iron deficiency, fatigue, dizziness), negative impacts on work productivity, and poor venous access in older adults.
Unmet needs related to PV are more prevalent among specific patient groups, including younger patients who require longer treatment durations, those of reproductive age, those with a high phlebotomy burden, and those living in rural or remote communities.
The clinical experts consulted by CDA-AMC indicated that ropeginterferon alfa-2b can be used as first-line therapy or after the failure of first-line or second-line treatment for PV. The Canadian MPN group indicated that ropeginterferon alfa-2b would be appropriate as a first-line or early-line cytoreductive drug, particularly among younger patients or those with longer anticipated disease duration. The Ontario Health (Cancer Care Ontario) Hematology Cancer Drug Advisory Committee indicated that all patients should receive ropeginterferon alfa-2b for any line of treatment, regardless of risk category.
The participating public drug programs provided input regarding considerations for initiation of therapy.
With a vote of 11 in favour to 4 against, pERC recommends that ropeginterferon alfa-2b be reimbursed for the treatment of adult patients with PV requiring cytoreductive therapy, only if the conditions listed in Table 1 are met.
Table 1: Reimbursement Conditions and Reasons
Reimbursement condition | Reason | Implementation guidance |
|---|---|---|
Initiation | ||
1. Treatment with ropeginterferon alfa-2b should be reimbursed when initiated in patients with PV requiring cytoreductive treatment who meet the following criteria: 1.1. aged 18 years or older 1.2. confirmed diagnosis of polycythemia vera 1.3. good performance status. | Evidence from the PROUD-PV and LTE CONTINUATION-PV trials demonstrated that treatment with ropeginterferon alfa-2b resulted in a clinically meaningful benefit in patients with these characteristics. Patients with an ECOG PS score of greater than 2 were excluded from the trial. | Condition 1.3: pERC agreed with the clinical experts consulted by CDA-AMC that patients with ECOG PS scores of greater than 2 should not be considered eligible for treatment with ropeginterferon alfa-2b. |
2. Adult patients who require cytoreductive treatment but have not received any treatment previously, should meet 1 or more of the following: 2.1. aged older than 60 years 2.2. previously documented cardiovascular or thromboembolic event(s) 2.3. poor tolerance to phlebotomy 2.4. progressive splenomegaly 2.5. elevated platelet counts or thrombocytosis 2.6. leukocytosis. | This is to align with the clinical evidence from the PROUD-PV and LTE CONTINUATION-PV trials. | Condition 2.3: In the PROUD-PV trial, poor tolerance was defined as 1 of the following:
Condition 2.4: In the PROUD-PV trial, progressive splenomegaly was defined as de novo appearance of a palpable spleen or appearance of the symptoms, related to the enlarged spleen (e.g., pain, early satiety, and so forth), with confirmed size increase. Condition 2.5: In the PROUD-PV trial, an elevated platelet count was defined as platelet counts greater than 1,000 × 109/L (for 2 measurements within 1 week). Condition 2.6: In the PROUD-PV trial, leukocytosis was defined as white blood count > 10 × 109/L for 2 measurements within 1 week. |
3. Adult patients who require cytoreductive treatment and are currently treated or have been pretreated with hydroxyurea, should have 1 of the following: 3.1. documented resistance to hydroxyurea 3.2. intolerance to hydroxyurea. | This is to align with the clinical evidence from the PROUD-PV and CONTINUATION-PV trials. | The documented resistance or intolerance to hydroxyurea should be determined by the treating physician. pERC agreed with the clinical experts that for patients with PV currently receiving first-line hydroxyurea for cytoreductive therapy, switching to ropeginterferon alfa-2b for a limited period at the time of implementation would be reasonable, provided these patients have documented resistance or intolerance to hydroxyurea. |
Discontinuation | ||
4. Treatment should be discontinued upon the occurrence of either of the following: 4.1. disease progression 4.2. unacceptable toxicity. | Patients in the PROUD-PV and CONTINUATION-PV trials discontinued treatment upon disease progression and unacceptable toxicity. | — |
Prescribing | ||
5. Ropeginterferon alfa-2b should be prescribed by a clinician experienced in the diagnosis and management of PV. | This is meant to ensure that ropeginterferon alfa-2b is prescribed for appropriate patients. | — |
Pricing | ||
6. The cost of ropeginterferon alfa-2b should be negotiated so that it does not exceed the cost of treatment with the least costly cytoreductive treatment reimbursed for the same indication. | Based on the committee’s assessment of the evidence, ropeginterferon alfa-2b is expected to have broadly comparable benefits and harms compared with hydroxyurea. The comparative effectiveness of ropeginterferon alfa-2b with peginterferon alfa-2a is uncertain. Therefore, the total cost of ropeginterferon alfa-2b should be no more than the least costly cytoreductive treatment reimbursed for this indication. | — |
Feasibility of adoption | ||
7. The economic feasibility of adoption of ropeginterferon alfa-2b must be addressed. | At the submitted price, the incremental budget impact of ropeginterferon alfa-2b is expected to be greater than $40 million in years 2 and 3. | — |
CDA-AMC = Canada’s Drug Agency; ECOG PS = Eastern Cooperative Oncology Group Performance Status; LTE = long-term extension; pERC = pan-Canadian Oncology Drug Review Expert Review Committee; PV = polycythemia vera.
Based on the totality of the clinical evidence, pERC concluded that it is uncertain whether ropeginterferon alfa-2b demonstrates acceptable clinical value compared with appropriate comparators including hydroxyurea, peginterferon alfa-2a, and ruxolitinib. Given that ropeginterferon alfa-2b is expected to be an alternative to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea.
Evidence from 1 phase III randomized controlled trial (PROUD-PV; N = 257) showed at 12 months of treatment that the disease response rate was 21.3% for the ropeginterferon alfa-2b group and 27.6% for the hydroxyurea group (between-group difference = -███ [95% confidence interval [CI], █████ to ███]). Ropeginterferon alfa-2b failed to demonstrate noninferiority to hydroxyurea at 12 months because the lower bound of the 95% CI exceeded the noninferiority margin of −10.5%.
Evidence from the PROUD-PV trial showed that compared with hydroxyurea, treatment with ropeginterferon alfa-2b for 12 months likely resulted in similar clinical benefit for adult patients with PV in terms of the proportions of patients achieving disease response (between-group difference = █████%; 95% CI, ██████ to ████), durable disease response (between-group difference = █████%; 95% CI, █████ ██ ████), and complete hematological response (between-group difference = −3.02%; 95% CI, −15.55% to 9.52%). Data from the PROUD-PV trial also indicated that compared with hydroxyurea, treatment with ropeginterferon alfa-2b may result in little to no clinically important difference in health-related quality of life (HRQoL) (as measured by change in the EQ visual analogue scale (VAS) from baseline to 12 months) among adult patients with PV. In the PROUD-PV trial, the mean number of phlebotomies per patient and visit during the study was numerically higher among patients in the ropeginterferon alfa-2b group (0.19; range, 0 to 10) versus patients in the hydroxyurea group (0.16; range, 0 to 12).
Key limitations of the PROUD-PV trial include its open-label design and high rates of missing data for the HRQoL results. According to the clinical experts consulted for this review, a follow-up period of 12 months is insufficient to observe the full treatment response of ropeginterferon alfa-2b. In addition, an important generalizability concern is that the slow titration dose escalation of ropeginterferon alfa-2b used in the PROUD-PV trial does not align with current practice where a more rapid dose escalation may achieve faster hematological responses.
Evidence from the completed long-term extension of the PROUD-PV trial (the CONTINUATION-PV study) suggested that at 36 months, ropeginterferon alfa-2b was associated with numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden, when compared with best available therapy. Similar changes in EQ VAS from baseline to 36 months were observed for the ropeginterferon alfa-2b and best available therapy groups. After more than 7 years of follow-up, treatment with ropeginterferon alfa-2b was associated with a higher probability of event-free survival (defined as an absence of thrombotic events, myelofibrosis, acute myeloid leukemia, or death) compared with best available therapy. pERC noted that the key limitation of the CONTINUATION-PV study was its enrichment study design by enrolling patients who demonstrated benefit in the PROUD-PV trial which might have resulted in the overestimation of efficacy and underestimation of harms.
Overall, the results of the matching-adjusted indirect comparison (MAIC) suggested that ropeginterferon alfa-2b may result in little to no difference in complete response at 24 and 36 months when compared with peginterferon alfa-2a. However, pERC noted that the indirect comparison was subject to considerable limitations and uncertainty preventing any firm conclusions to be made regarding comparative efficacy. pERC also noted that there remains a gap in the evidence regarding the efficacy and harms of ropeginterferon alfa-2b compared to other treatments commonly used in clinical practice in Canada.
Further information on the committee’s discussion around clinical value is provided in the Summary of Deliberation section.
pERC also established that there is significant unmet clinical need for additional cytoreductive treatment options for PV. PV is a rare disease, as the incidence in Canada is estimated at around 2 per 100,000 per year. Untreated PV carries a potentially life-threatening risk of thrombosis and hemorrhagic complications. There is also the risk of progression to myelofibrosis and acute myeloid leukemia. pERC noted that there are currently limited treatment options available, and hydroxyurea, used off-label, is the most commonly used first-line cytoreductive treatment for these patients. Other treatment options include peginterferon alfa-2a which may not be available in all jurisdictions and ruxolitinib is available as a second-line treatment, after resistance or intolerance to hydroxyurea. In addition, hydroxyurea does not have disease modifying properties and does not target JAK2 mutation, where they have been identified as unmet needs by patients and clinicians. There is also the challenge where some patients develop intolerance or resistance to hydroxyurea; hydroxyurea is associated with unique toxicities such as development of mouth and skin ulcers, fatigue, myelosuppression, and increased risk of nonmelanoma skin cancer. Further, hydroxyurea is teratogenic and may not be suitable for those of reproductive age. Of note, the Health Canada product monograph for Hydrea (hydroxyurea) recommends that “female patients of reproductive potential should be counselled to use effective contraception during therapy and for at least 6 months after therapy” and “men under therapy are advised to use safe contraceptive measures during and at least 1 year after therapy.” The committee also acknowledged that the need for additional cytoreductive treatment options for PV may also be driven by supply shortages of both hydroxyurea and peginterferon alfa-2a in some jurisdictions and there is a significant unmet need, particularly for patients with intolerance or contraindications to hydroxyurea.
pERC concluded that ropeginterferon alfa-2b addresses a significant unmet need to a degree that justifies a positive recommendation despite the uncertainty in clinical value.
Further information on the committee’s discussion around unmet clinical need is provided in the Summary of Deliberation section.
Due to the uncertainty in clinical value, pERC could not recommend whether to reimburse ropeginterferon alfa-2b based on clinical value alone. Therefore, the committee also considered whether ropeginterferon alfa-2b addresses a significant unmet clinical need. pERC concluded that ropeginterferon alfa-2b addresses a significant unmet clinical need with an acceptable level of certainty. Based on the preceding considerations, pERC recommended that ropeginterferon alfa-2b be reimbursed. As part of the deliberation on whether to recommend reimbursement, the committee also considered unmet nonclinical need and health inequity. Information on this discussion is provided in the Distinct Social and Ethical Considerations domain in the Summary of Deliberation section.
Because pERC recommended that ropeginterferon alfa-2b be reimbursed, the committee also deliberated on whether reimbursement conditions should be added to address important economic considerations, health system impacts, or social and ethical considerations, or to ensure clinical value is realized. The resulting reimbursement conditions, with accompanying reasons and implementation guidance, are stated in Table 1.
pERC considered all domains of value of the deliberative framework before developing its recommendation: clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on health systems. For further information on the domains of value, refer to Expert Committee Deliberation at Canada’s Drug Agency.
The committee considered the following key discussion points, organized by the 5 domains of value.
Appropriate comparators: pERC acknowledged that the submitted evidence captured several relevant comparator treatments for PV in Canada, which included hydroxyurea (assessed in the pivotal PROUD-PV trial), peginterferon alfa-2a (assessed in the sponsor-submitted MAIC), and standard phlebotomy plus acetylsalicylic acid (ASA) (assessed in the Low-PV trial). Of note, the CONTINUATION-PV trial compared ropeginterferon alfa-2b with best available therapy, with approximately 97% of patients in the best available therapy arm receiving hydroxyurea as their primary treatment at 36 months. pERC highlighted the lack of comparative evidence between ropeginterferon alfa-2b and ruxolitinib, which is approved by Health Canada for the treatment of PV following resistance or intolerance to hydroxyurea.
Efficacy versus hydroxyurea: Evidence from 1 phase III randomized controlled trial (PROUD-PV; N = 257) showed that compared with hydroxyurea, treatment with ropeginterferon alfa-2b for 12 months likely resulted in similar clinical benefit for adult patients with PV in terms of the proportions of patients achieving disease response (between-group difference = -█████; 95% CI, ██████ to ████), durable disease response (between-group difference = █████%; 95% CI, █████ to ████), and complete hematological response (between-group difference = −3.02%; 95% CI, −15.55% to 9.52%). The PROUD-PV trial also demonstrated that compared with hydroxyurea, treatment with ropeginterferon alfa-2b may result in little to no clinically important difference in HRQoL (as measured by change in EQ VAS from baseline to 12 months) among adult patients with PV. Conclusions for HRQoL were limited by the open-label design of the trial and high rates of missing data at month 12.
Although not formally included in the Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment, treatment with ropeginterferon alfa-2b for 12 months was associated with a numerical decrease in the percent reduction in JAK2 burden from baseline (between-group difference = 3.78%; 95% CI, −0.67% to 8.34%) and the proportion of patients achieving molecular response (between-group difference = −8.07%; 95% CI, −19.99% to 3.84%) compared with hydroxyurea. In the PROUD-PV trial, the mean number of phlebotomies performed per patient and per visit during the study was numerically higher among patients in the ropeginterferon alfa-2b group (0.19; range, 0 to 10) versus patients in the hydroxyurea group (0.16; range, 0 to 12).
Efficacy versus best available therapy: Evidence from the long-term extension CONTINUATION-PV trial suggests that at 36 months, ropeginterferon alfa-2b was associated with numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden, when compared with best available therapy. Similar changes in EQ VAS from baseline to 36 months were observed for the ropeginterferon alfa-2b and best available therapy groups. After more than 7 years of follow-up, evidence from the CONTINUATION-PV trial suggested that treatment with ropeginterferon alfa-2b is associated with a higher probability of event-free survival (defined as an absence of thrombotic events, myelofibrosis, or death) compared with best available therapy. However, key limitations of the LTE trial included enrolment of only patients who showed benefit in the PROUD-PV trial, lack of recalculation of statistical power, limited methods of handling missing data, and a longer median treatment duration in the ropeginterferon alfa-2b group.
Additional studies addressing gaps in evidence: The sponsor submitted 2 studies that addressed gaps in the evidence from the PROUD-PV and CONTINUATION-PV trials.
The PEGINVERA study was a phase I/II study, which evaluated ropeginterferon alfa-2b among 51 patients with PV. This study evaluated the efficacy and safety of ropeginterferon alfa-2b in patients with more advanced PV (e.g., longer disease duration and exposure to prior treatments) compared with the PROUD-PV and CONTINUATION trials.
The Low-PV trial was a phase II, open-label, randomized trial with a group sequential adaptive design that compared ropeginterferon alfa-2b plus phlebotomy and ASA to phlebotomy plus ASA in 127 patients with low-risk PV.
pERC acknowledged that evidence from these studies supported the efficacy of ropeginterferon alfa-2b. However, the committee also acknowledged that the results from the studies were associated with high uncertainty due to key limitations. For instance, the PEGINVERA study had a small sample size with no comparator group. The Low-PV trial was limited due to its open-label crossover design, limited long-term follow-up, and uncertain generalizability to patients who require cytoreductive therapy.
Clinical importance of treatment effects: pERC considered that the outcomes assessed in the submitted evidence were important to patients with PV and aligned with key unmet clinical needs. The outcomes that were identified as most relevant by patients and clinicians were disease control, HRQoL, symptom control, reduced phlebotomy burden, reduction in thrombotic events and secondary malignancies, and safety.
Based on the results of the 12-month PROUD-PV trial, pERC highlighted that ropeginterferon alfa-2b likely demonstrates little to no meaningful difference in disease response rate, durable response rate, and complete hematological response rate compared with hydroxyurea. The committee also acknowledged that ropeginterferon alfa-2b may demonstrate little to no benefit in HRQoL from baseline to 12 months, although results were uncertain due to open-label trial design and high rates of missing data. pERC also emphasized that reducing phlebotomy burden is an important outcome, but pERC noted that treatment with ropeginterferon alfa-2b did not result in the reduction of phlebotomies among patients in the PROUD-PV trial compared with the control of the study. pERC acknowledged the input by clinical experts that the study period of 12 months in the PROUD-PV trial was not sufficient to demonstrate the long-term benefits and clinical importance of the treatment effects of ropeginterferon alfa-2b.
Based on more than 7 years of follow-up of the LTE CONTINUATION-PV trial, the committee highlighted that ropeginterferon alfa-2b was associated with improved event-free survival and reduced incidences of thrombotic events, and progressions to myelofibrosis and acute myeloid leukemia. Although pERC acknowledged that the results of the CONTINUATION-PV trial suggested long-term benefits of ropeginterferon alfa-2b, they considered these results to be supportive evidence due to key limitations of the study. These included the enrolment of only those who responded from the PROUD-PV trial, the lack of rerandomization of patients, limited description of handling of missing data, and differences in treatment duration between groups. pERC acknowledged that no new safety signals of ropeginterferon alfa-2b were identified in the submitted evidence.
Observed delay in efficacy of ropeginterferon alfa-2b between the PROUD-PV and CONTINUATION-PV trials: pERC noted that improvements in important outcomes of PV resulting from treatment with ropeginterferon alfa-2b were demonstrated over a longer duration of follow-up, based on the results of the PROUD-PV and CONTINUATION-PV trials. The committee acknowledged the clinical experts’ attribution of the observed delay in efficacy to the titration schedule of ropeginterferon alfa-2b used in the trials. The clinical experts further explained that the trials used a low dose, slow escalation approach to administer ropeginterferon alfa-2b to patients. However, the clinical experts highlighted that an accelerated approach was also used in clinical practice and was more likely to result in faster efficacy of the drug compared to the approach used in the trials. The clinical experts also confirmed that in clinical practice, the accelerated approach does not result in more or different safety signals compared to the low dose, slow escalation approach. However, the clinical evidence submission did not include any studies investigating differences in dosing approaches of ropeginterferon alfa-2b.
Certainty of the evidence: pERC discussed the certainty of evidence as assessed using the GRADE method. The GRADE assessment rated the certainty of evidence as moderate for disease response rate and durable disease response rate (downgraded 1 level due to serious imprecision in the effect estimates). Moreover, evidence for complete hematological response rate at 12 months was rated as moderate, (downgraded 1 level due to concerns related to the risk of bias). In particular, assessment of noninferiority for this outcome was presented in the results of the Clinical Study Report but was not prespecified in the study protocol or statistical analysis plan. The GRADE assessment rated the certainty of evidence for HRQoL as low (downgraded 2 levels for risk of bias due to its open-label study design and high rates of missing data for this outcome at 12 months).
Efficacy versus peginterferon alfa-2a and ruxolitinib: The sponsor submitted 1 MAIC that compared complete hematological response of ropeginterferon alfa-2b to peginterferon alfa-2a among adult patients with PV. The results of the MAIC suggested that ropeginterferon alfa-2b may result in little to no difference in complete hematological response at 24 and 36 months when compared with peginterferon alfa-2a. However, due to significantly reduced effective sample size (███ █████████) and presence of wide 95% credible intervals, there may be a lack of precision in the effect estimates. In addition, the MAIC was further limited by heterogeneity in baseline characteristics across the included trials, which may have resulted in a biased estimate of comparative efficacy. Specifically, the MPD-RC 112 study included patients with both high risk of essential thrombocythemia and PV and most covariates were adjusted to the overall population (combined characteristics of essential thrombocythemia and PV), except for age and sex, which could compromise the comparability of the target trial and the index population in the indirect comparison.
Due to a paucity of evidence, ruxolitinib was not included as a comparator in the MAIC. Moreover, there remains an evidence gap in how ropeginterferon alfa-2b compares to other relevant treatments for PV in Canada in terms of other efficacy outcomes and harms.
Clinical value: Based on all the preceding considerations, the committee determined that there was uncertainty in the clinical value versus appropriate comparators for PV (i.e., hydroxyurea, peginterferon alfa-2b, and ruxolitinib).
Input on unmet clinical need: pERC acknowledged that patients with PV identified a need for treatments that address the underlying disease mechanisms of PV, reduce symptom burden and treatment-related side effects, and improve quality of life. Patients also expressed a need for treatments that reduce phlebotomy-related burden, which is a major driver of work absenteeism among patients and their caregivers. pERC noted that the clinician group input also highlighted a need for treatments that reduce clonal burden and reduce the risk of disease transformation, noting that current treatments do not reliably achieve molecular response or reduction in JAK2 V617F allele burden. In addition to impacts on work productivity, pERC noted that clinicians highlighted additional limitations to phlebotomy, such as poor tolerance, geographic barriers, iron deficiency, and side effects leading to poor adherence (e.g., fatigue, dizziness). pERC also noted the clinicians’ input indicating additional unmet needs among younger patients (as they are expected to live longer with the disease), those of reproductive age (limited treatment options), those with high phlebotomy burden, and those living in rural or remote communities.
Severity of the disease: pERC acknowledged that PV is a chronic myeloproliferative neoplasm that is associated with life-threatening complications. The committee highlighted that PV is associated with an estimated 3-fold higher risk of arterial thrombosis and a 13-fold higher risk of venous thrombosis, and hemorrhagic complications occur in 15% to 35% of patients. Moreover, pERC noted that PV is associated with long-term risks of progression to myelofibrosis and acute leukemia, which was highlighted as a concern among younger patients with anticipated longer duration of disease. Approximately 10% of patients develop post-PV myelofibrosis, and the estimated risks of leukemic transformation are 2.3% at 10 years and 5.5% at 15 years following diagnosis. pERC acknowledged patients’ and clinicians’ input indicating that despite availability of treatments for PV, patients continue to experience substantial symptoms and treatment burden and diminished quality of life. The committee acknowledged that patients with PV experience negative impacts on employment, social activities, daily functioning, and frequent phlebotomies and clinic visits.
Availability of treatment options: pERC acknowledged that although recommended for all patients with PV, phlebotomy in combination with ASA is associated with side effects (e.g., iron deficiency, fatigue, dizziness) and procedural burden. pERC noted that hydroxyurea is used off-label as a first-line cytoreductive drug for PV in Canada. The committee acknowledged that hydroxyurea is associated with numerous toxicities (e.g., development of ulcers, myelosuppression, and increased risk of nonmelanoma skin cancer) and may be unsuitable for those of reproductive age due to its teratogenic properties. pERC noted that second-line and later-line cytoreductive drugs include the off-label interferon-based therapies (e.g., peginterferon alfa-2a) and ruxolitinib. The committee acknowledged that clinicians also highlighted inconsistent access to interferon-based therapies across Canada, which is a significant unmet need for a chronic condition requiring long-term therapy. The committee also noted that ruxolitinib is approved by Health Canada for the treatment of PV following resistance or intolerance to hydroxyurea.
Evidence generation: pERC acknowledged that challenges in evidence generation for PV include rarity of the disease (incidence approximately 2 per 100,000 persons per year in Canada) and the limited number of eligible patients available for clinical trials. The committee further noted that the evidence base consisted of studies with small sample sizes, which contributed to uncertainty in the evidence.
Significant unmet clinical need: pERC acknowledges that despite available treatment options for PV, patients continue to experience substantial morbidity, including thrombotic complications, risk of progression to myelofibrosis or acute myeloid leukemia, ongoing symptom burden, and treatment-related burden. The committee also acknowledged the rarity of PV and limited number of eligible patients available for clinical trials. Due to challenges with evidence generation associated with the rarity of PV and the severity of the disease despite available treatment options, pERC considered there to be significant unmet need as described in the recommendation framework in the Procedures for Reimbursement Reviews.
Input on unmet nonclinical need: pERC acknowledged that patients with PV, especially those living in rural communities, often face geographic barriers around access to specialist care and phlebotomies. The committee noted that this barrier can worsen financial (e.g., increased travel costs and productivity loss) and psychological burden. In addition, pERC acknowledged the patients’ and clinicians’ input indicating that access to interferon-based therapy remains inconsistent in Canada, which may disproportionately affect younger patients, those of reproductive age, and patients living in rural or remote communities. Based on the patient group input, the committee noted that phlebotomies are costly to health care systems compared to other treatment options, such as oral therapy or home-based injection.
Equity considerations: pERC acknowledged that PV disproportionately affects several patient groups, such as patients living in remote and rural communities (increased travel burden to specialists and treatment centres), racialized populations (may experience increased complication burden, such as higher rates of hemorrhage and thrombosis, compared with patients who are white), younger patients (may experience increased complication burden, with higher rates of hemorrhage and thrombosis reported among patients in other racialized populations), and those of reproductive age (face limited treatment options due to teratogenic effects of hydroxyurea). The committee noted that the submitted evidence was conducted among predominantly white patients in Europe, which limited the assessment of impacts of ropeginterferon alfa-2b among patients in other racialized populations.
Ethical implications: pERC did not identify any specific implications related to informed consent, stigma, confidentiality, patient privacy, or additional procedures associated with ropeginterferon alfa-2b.
Health impacts of ropeginterferon alfa-2b versus relevant comparators: Based on the output of the economic model, ropeginterferon alfa-2b may be associated with a gain of 0.07 life-years compared to hydroxyurea and may result in a gain of 0.14 quality-adjusted life-year compared to hydroxyurea over a 42-year horizon. Due to limitations with the comparative evidence, pERC concluded that it is uncertain whether ropeginterferon alfa-2b demonstrates acceptable clinical value compared with appropriate comparators including hydroxyurea, peginterferon alfa-2a, and ruxolitinib. Given that ropeginterferon alfa-2b is expected to be an alternative to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea.
Cost of ropeginterferon alfa-2b versus relevant comparators: Based on the output of the economic model, ropeginterferon alfa-2b is predicted to be associated with higher costs to health care systems than hydroxyurea (incremental costs = $738,474) over a 42-year horizon, primarily driven by increased costs associated with drug acquisition.
Key findings of the economic evaluation: Based on the submitted evidence using the sponsor’s cost-utility analysis, the CDA-AMC base-case analysis estimated that the incremental cost-effectiveness ratio for ropeginterferon alfa-2b in adult patients with PV requiring cytoreductive therapy was $5,136,642 per quality-adjusted life-year gained when compared with hydroxyurea. The cost-effectiveness estimate is uncertain due to limitations with the comparative clinical evidence. Given the conclusions by pERC regarding the clinical evidence, the total cost of ropeginterferon alfa-2b should be no more than the least costly cytoreductive treatment reimbursed for this indication.
Anticipated budget impact: The budget impact of reimbursing ropeginterferon alfa-2b for the treatment of PV in the reimbursement requested population will be approximately $129 million over the first 3 years of reimbursement compared to the amount currently spent on comparators, with an estimated expenditure of $153 million on ropeginterferon alfa-2b over this period. The actual budget impact of reimbursing ropeginterferon alfa-2b will depend on the eligible patient population, market share assumptions, and assumptions regarding ropeginterferon alfa-2b dosing.
pERC noted that the formulation of ropeginterferon alfa-2b may lead to wastage during the dose titration phase, as ropeginterferon alfa-2b is currently only available as a single-use prefilled 500 mcg syringe for injection.
To make its recommendation, the committee considered the following information (links to the full documents for the review can be found on the project web page):
the CDA-AMC review of the clinical and pharmacoeconomic evidence submitted by the sponsor, as well as relevant ethical issues related to ropeginterferon alfa-2b (refer to the Main Report and Supplemental Material document)
the sponsor’s comments on the draft report and the CDA-AMC responses
patients' perspectives gathered by 2 patient groups, 1 submission from Heal Canada and 1 joint submission from the Leukemia & Lymphoma Society of Canada and the Canadian MPN Network (refer to the Patient and Clinician Group Input document)
input from 2 clinician groups, 1 from the Canadian MPN Group and 1 from the Ontario Health (Cancer Care Ontario) Hematology Cancer Drug Advisory Committee (refer to the Patient and Clinician Group Input document)
input from public drug programs that participate in the reimbursement review process (refer to the Supplemental Material document)
input from 3 clinical experts with expertise in the management of PV consulted by CDA-AMC.
All feedback received in response to the draft recommendation is available on the CDA-AMC project web page.
Dr. Catherine Moltzan (Chair), Dr. Kelvin Chan (Vice-Chair), Paul Agbulu, Dr. Phillip Blanchette, Dr. Matthew Cheung, Annette Cyr, Dr. Jennifer Fishman, Dr. Prafull Ghatage, Dr. Jason Hart, Terry Hawrysh, Dr. Yoo-Joung Ko, Dr. Aly-Khan Lalani, Amy Peasgood, Dr. Anca Prica, Dr. Michael Raphael, Dr. Adam Raymakers, Dr. Patricia Tang, Dr. Pierre Villeneuve, and Danica Wasney.
Meeting date: September 8, 2026
Regrets: Two expert committee members did not attend.
Conflicts of interest: One expert committee member did not participate due to considerations of conflict of interest.
ISSN: 2563-6596
Canada’s Drug Agency (CDA-AMC) is a pan-Canadian health organization. Created and funded by Canada’s federal, provincial, and territorial governments, we’re responsible for driving better coordination, alignment, and public value within Canada’s drug and health technology landscape. We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact.
Disclaimer: CDA-AMC has taken care to ensure that the information in this document was accurate, complete, and up to date when it was published, but does not make any guarantee to that effect. Your use of this information is subject to this disclaimer and the Terms of Use at cda-amc.ca.
The information in this document is made available for informational and educational purposes only and should not be used as a substitute for professional medical advice, the application of clinical judgment in respect of the care of a particular patient, or other professional judgments in any decision-making process. You assume full responsibility for the use of the information and rely on it at your own risk.
CDA-AMC does not endorse any information, drugs, therapies, treatments, products, processes, or services. The views and opinions of third parties published in this document do not necessarily reflect those of CDA-AMC. The copyright and other intellectual property rights in this document are owned by the Canadian Agency for Drugs and Technologies in Health (operating as CDA-AMC) and its licensors.
Questions or requests for information about this report can be directed to Requests@CDA-AMC.ca.